TY  - JOUR
A1  - Ballo, Olivier Karl Friedrich
A1  - Eladly, Fagr
A1  - Koschade, Sebastian E.
A1  - Büttner, Stefan
A1  - Stratmann, Jan Alexander
A1  - Brunnberg, Uta
A1  - Kreisel, Eva-Maria
A1  - Frank, Franziska
A1  - Wagner, Sebastian
A1  - Steffen, Björn
A1  - Serve, Hubert
A1  - Finkelmeier, Fabian
A1  - Brandts, Christian Hubertus
T1  - Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy
T2  - Annals of hematology
N2  - Treatment‐related complications contribute substantially to morbidity and mortality in acute myeloid leukemia (AML) patients undergoing induction chemotherapy. Although AML patients are susceptible to fluid overload (FO) (e.g., in the context of chemotherapy protocols, during sepsis treatment or to prevent tumor lysis syndrome), little attention has been paid to its role in AML patients undergoing induction chemotherapy. AML patients receiving induction chemotherapy between 2014 and 2019 were included in this study. FO was defined as ≥5% weight gain on day 7 of induction chemotherapy compared to baseline weight determined on the day of admission. We found FO in 23 (12%) of 187 AML patients undergoing induction chemotherapy. Application of >100 ml crystalloid fluids/kg body weight until day 7 of induction chemotherapy was identified as an independent risk factor for FO. AML patients with FO suffered from a significantly increased 90-day mortality rate and FO was demonstrated as an independent risk factor for 90-day mortality. Our data suggests an individualized, weight-adjusted calculation of crystalloid fluids in order to prevent FO-related morbidity and mortality in AML patients during induction chemotherapy. Prospective trials are required to determine the adequate fluid management in this patient population.
KW  - Fluid overload
KW  - Acute myeloid leukemia
KW  - Induction chemotherapy
KW  - Survival
KW  - Intensive care treatment
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63807
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-638070
SN  - 1432-0584
N1  - Open Access funding enabled and organized by Projekt DEAL.
VL  - 100
IS  - 10
SP  - 2603
EP  - 2611
PB  - Springer
CY  - Berlin ; Heidelberg ; New York
ER  -